Prevalence of metabolic syndrome, clinical severity and quality of life in patients with psoriasis at the Hospital Universitario de La Samaritana.
DOI:
https://doi.org/10.29176/2590843X.255Keywords:
Psoriasis, quality of life, metabolic syndromeAbstract
Introduction: Psoriasis is recognized as a systemic disease, and some studies have associated this disease with other entities, such as the metabolic syndrome, which has a significant association with an increased risk of cardiovascular events. Its impact on patients´ lives is not only related with the physical, but also with the other components of quality of life, including psychological, social, sexual and occupational elements.
Materials and methods: A prospective and descriptive study that included patients with psoriasis was made; Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were measured; and the presence of metabolic syndrome components based on the criteria of the International Diabetes Federation (IDF) to South American populations was established.
Results: We included 52 patients, 26 men and 26 women, whose age range was located mainly between 41 and 64 years old (69.2%), psoriasis was mostly mild in 67.3%, quality of life was affected in 84.6% of patients. Metabolic syndrome was present in 59.6% and psoriatic arthritis in 19.2%.
Conclusion: The results of this study will become a baseline of the behavior of psoriasis in a Colombian population, because nowadays there is little information about this topic.
Author Biographies
Rolando Rojas
Médico dermatólogo, Universidad Nacional de Colombia, Bogotá, D.C., Colombia
Héctor Castellanos
Médico dermatólogo; profesor asociado de Dermatología, Universidad Nacional de Colombia, Bogotá, D.C., Colombia
Elkin Peñaranda
Médico dermatólogo oncólogo; coordinador, Servicio de Dermatología, Hospital Universitario de La Samaritana, Bogotá, D.C., Colombia.
References
1. Trujillo IA, Díaz-García MA, Torres-Gemeil O, Torres-Barbosa F, Falcón-Lincheta L, Pérez-Hernández M. Psoriasis vulgar. Estudio descriptivo de 200 pacientes. Rev Cubana Med. 2002;41:12-5.
2. González C, Castro LA, De La Cruz G, Arenas CM, Beltrán A, Santos AM. Caracterización epidemiológica de la psoriasis en el Hospital Militar Central. Rev Asoc Colomb Dermatol. 2009;17:11-7.
3. Vélez N, Bohórquez L, Corrales MF, Orrego S, Jiménez SB, Zuluaga A, et al. Caracterización de los pacientes con psoriasis en tratamiento con fototerapia. Rev Asoc Colomb Dermatol. 2011;19:100-6.
4. Ramos E, Gioppo J, Miret M, Guzmán Y, Endara M. Factores de riesgo cardiovascular en pacientes con psoriasis. Dermatol Venez. 2008;46:11-8.
5. Carbo E, Leban V, Federico D, Williner ME, Díaz MG, Guardati MV, et al. Psoriasis y síndrome metabólico: estudio restrospectivo sobre 22 casos. Rev Argent Dermatol. 2010;91:1-15.
6. Mussallam S, Meza B, Elescano I. Síndrome metabólico como factor asociado a psoriasis en la consulta dermatológica. Centro Médico Naval “CMST”, 2009. Folia Dermatol Perú. 2010;21:67-70.
7. Acosta-Medina D, Alfonso-Trujillo I, Toledo-García M. Calidad de vida, actividad y severidad de la psoriasis en pacientes de un policlínico de La Habana-Cuba. Enero-julio 2008. Dermatol Perú. 2009;19:44-7.
8. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol. 2010;130:1213-26.
9. Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol. 2007;25:535-46.
10. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9.
11. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl.2):31-5.
12. Ho P, Barton A, Worthington J. Genetic epidemiology of psoriatic arthritis. Mod Rheumatol. 2004;14:91-100.
13. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl.2):14-7.
14. Sánchez-Regaña M, Umbert P. Diagnosis and management of nail psoriasis. Actas Dermosifiliogr. 2008;99:34-43.
15. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614-21.
16. Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186-96.
17. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194-9.
18. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-35.
19. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
20. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000-6.
21. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271-6.
22. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. Br J Dermatol. 2010;163:586-92.
23. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
24. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-5.
25. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
26. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
27. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1-9.
28. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383-92.
29. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-5.
30. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(Suppl.2):57-61.
2. González C, Castro LA, De La Cruz G, Arenas CM, Beltrán A, Santos AM. Caracterización epidemiológica de la psoriasis en el Hospital Militar Central. Rev Asoc Colomb Dermatol. 2009;17:11-7.
3. Vélez N, Bohórquez L, Corrales MF, Orrego S, Jiménez SB, Zuluaga A, et al. Caracterización de los pacientes con psoriasis en tratamiento con fototerapia. Rev Asoc Colomb Dermatol. 2011;19:100-6.
4. Ramos E, Gioppo J, Miret M, Guzmán Y, Endara M. Factores de riesgo cardiovascular en pacientes con psoriasis. Dermatol Venez. 2008;46:11-8.
5. Carbo E, Leban V, Federico D, Williner ME, Díaz MG, Guardati MV, et al. Psoriasis y síndrome metabólico: estudio restrospectivo sobre 22 casos. Rev Argent Dermatol. 2010;91:1-15.
6. Mussallam S, Meza B, Elescano I. Síndrome metabólico como factor asociado a psoriasis en la consulta dermatológica. Centro Médico Naval “CMST”, 2009. Folia Dermatol Perú. 2010;21:67-70.
7. Acosta-Medina D, Alfonso-Trujillo I, Toledo-García M. Calidad de vida, actividad y severidad de la psoriasis en pacientes de un policlínico de La Habana-Cuba. Enero-julio 2008. Dermatol Perú. 2009;19:44-7.
8. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol. 2010;130:1213-26.
9. Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol. 2007;25:535-46.
10. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9.
11. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl.2):31-5.
12. Ho P, Barton A, Worthington J. Genetic epidemiology of psoriatic arthritis. Mod Rheumatol. 2004;14:91-100.
13. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl.2):14-7.
14. Sánchez-Regaña M, Umbert P. Diagnosis and management of nail psoriasis. Actas Dermosifiliogr. 2008;99:34-43.
15. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614-21.
16. Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186-96.
17. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194-9.
18. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-35.
19. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
20. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000-6.
21. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271-6.
22. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. Br J Dermatol. 2010;163:586-92.
23. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
24. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-5.
25. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
26. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
27. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1-9.
28. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383-92.
29. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-5.
30. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(Suppl.2):57-61.
How to Cite
1.
Rojas R, Castellanos H, Peñaranda E. Prevalence of metabolic syndrome, clinical severity and quality of life in patients with psoriasis at the Hospital Universitario de La Samaritana. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2013 Jul. 1 [cited 2024 Jul. 22];21(3):220-5. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/255
Downloads
Download data is not yet available.
Downloads
Published
2013-07-01
How to Cite
1.
Rojas R, Castellanos H, Peñaranda E. Prevalence of metabolic syndrome, clinical severity and quality of life in patients with psoriasis at the Hospital Universitario de La Samaritana. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2013 Jul. 1 [cited 2024 Jul. 22];21(3):220-5. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/255
Issue
Section
Research Article
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
